Skip to main content
    D

    Denali Therapeutics Inc (DNLI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.08
    -0.66 (-3.52%)

    Market Cap: $3.00B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Denali Therapeutics Inc (DNLI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Denali Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$512.54M, operating cash flow was -$412.60M and free cash flow was -$422.10M. The quarter ended Sep 30, 2026 had revenue of $17.78M and net income of $70.13M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $555.34M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$330.53M+204.7%100.0%-59.5%-43.9%
    Dec 2022$108.46M+122.9%100.0%-314.2%-300.6%
    Dec 2021$48.66M-85.5%100.0%-607.8%-597.2%
    Dec 2020$335.66M+1158.2%100.0%18.7%21.2%
    Dec 2019$26.68M-79.3%100.0%-799.1%-740.7%
    Dec 2018$129.16MN/A100.0%-35.9%-28.1%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$330.53M$108.46M$48.66M$335.66M$26.68M$129.16M$0$0
    Gross profit$0$0$330.53M$108.46M$48.66M$335.66M$26.68M$129.16M$0$0
    Research and development$418.78M$396.44M$423.88M$358.73M$265.35M$212.62M$193.38M$143.18M$74.46M$75.70M
    Operating income-$555.34M-$487.34M-$196.70M-$340.74M-$295.75M$62.72M-$213.18M-$46.37M-$90.14M-$87.43M
    Net income-$512.54M-$422.77M-$145.22M-$325.99M-$290.58M$71.14M-$197.61M-$36.24M-$88.19M-$86.65M
    EBITDA-$540.53M-$478.35M-$179.97M-$330.36M-$278.41M$71.30M-$210.21M-$41.66M-$84.35M-$85.66M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$17.78M$3.60M$0$0$0$0$0$0$0$0$0-$305.04M
    Gross profit$17.59M$3.51M$0-$2.87M$0$0$0N/A$0$0$0-$307.22M
    Operating income-$126.75M-$130.54M-$137.36M-$137.37M-$137.43M-$134.96M-$145.58M-$129.85M-$123.19M-$116.59M-$117.72M-$132.57M
    Net income$70.13M-$127.55M-$128.45M-$128.55M-$126.90M-$124.12M-$132.97M-$114.75M-$107.19M-$99.03M-$101.80M-$119.47M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $9.55M by $195.78M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.14B$1.37B$1.15B$1.46B$1.40B$1.60B$553.23M$661.98M$486.72M$271.07M
    Current assets$900.66M$864.44M$1.06B$1.37B$897.23M$1.50B$430.03M$480.84M$409.61M$181.96M
    Cash and equivalents$205.33M$174.96M$127.11M$218.04M$293.48M$507.14M$79.45M$77.12M$218.38M$39.85M
    Total liabilities$131.09M$144.50M$122.96M$417.81M$441.87M$453.75M$158.34M$115.14M$20.93M$16.55M
    Short-term debt$9.55M$12.03M$7.26M$7.32M$5.45M$4.69M$3.67M$19.09MN/AN/A
    Shareholder equity$1.01B$1.23B$1.03B$1.04B$962.29M$1.15B$394.89M$546.85M$465.80M$254.52M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.26B$1.16B$1.27B$1.14B$1.06B$1.17B$1.27B$1.37B$1.45B$1.50B$1.58B$1.15B
    Total liabilities$329.65M$322.78M$339.93M$131.09M$129.42M$139.19M$148.66M$144.50M$135.52M$115.51M$125.62M$122.96M
    Cash and equivalents$102.87M$201.53M$387.63M$205.33M$90.96M$141.21M$56.95M$174.96M$90.64M$74.68M$60.57M$127.11M
    Shareholder equity$926.39M$835.18M$926.10M$1.01B$926.20M$1.03B$1.12B$1.23B$1.32B$1.39B$1.46B$1.03B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$412.60M-$347.69M-$357.99M-$244.72M-$211.39M$416.15M-$151.58M$50.12M-$76.64M-$71.91M
    Capital expenditures$9.50M$15.91M$12.94M$17.83M$8.50M$3.10M$17.92M$3.39M$2.88M$6.13M
    Free cash flow-$422.10M-$363.61M-$370.93M-$262.55M-$219.89M$413.06M-$169.50M$46.72M-$79.51M-$78.04M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$1.39M$0$0
    Investing cash flow$255.28M-$88.76M$249.31M-$141.39M-$21.63M-$623.21M$147.71M-$287.42M-$41.17M-$219.00M
    Financing cash flow$189.22M$484.30M$17.82M$310.67M$19.35M$634.75M$6.19M$97.02M$296.32M$300.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$117.44M-$97.00M-$131.20M-$98.54M-$107.30M-$75.30M-$131.47M-$83.72M-$59.14M-$91.22M-$113.62M-$98.66M
    Capital expenditures$1.01M$805.00K$2.47M$1.52M$1.38M$4.28M$5.08M$5.09M$3.88M$4.79M$2.15M$2.23M
    Free cash flow-$118.45M-$97.81M-$133.67M-$100.06M-$108.67M-$79.58M-$136.55M-$88.81M-$63.02M-$96.01M-$115.77M-$100.89M
    Last 12 quarters

    Frequently Asked Questions About DNLI

    What is Denali Therapeutics' annual revenue?

    Denali Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Denali Therapeutics profitable?

    No. Denali Therapeutics reported net income of -$512.54M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does DNLI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$412.60M minus capital expenditures of $9.50M produced free cash flow of -$422.10M.

    How much debt does Denali Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $9.55M and cash and equivalents of $205.33M.